PriceTargets.com logo

Beam Therapeutics - BEAM Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $45.58
  • Forecasted Upside: 57.67%
  • Number of Analysts: 16
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 2 Strong Buy Ratings
$28.91 As of 12/4/2025 05:00 PM ET
▲ +2.17 (8.12%)

This chart shows the closing price for BEAM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Beam Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BEAM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BEAM

Analyst Price Target is $45.58
▲ +57.67% Upside Potential
This price target is based on 16 analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $45.58, with a high forecast of $80.00 and a low forecast of $21.00. The average price target represents a 57.67% upside from the last price of $28.91.

This chart shows the closing price for BEAM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 16 contributing investment analysts is to moderate buy stock in Beam Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 2 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 2 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 3 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 3 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 2 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 2 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025Evercore ISIInitiated CoverageOutperform$35.00
11/24/2025Evercore ISIInitiated CoverageOutperform$35.00
11/17/2025BenchmarkReiterated RatingSpeculative Buy ➝ Speculative Buy
10/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00
10/9/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$48.00 ➝ $46.00
10/9/2025Jefferies Financial GroupInitiated CoverageHold ➝ Buy$41.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/15/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00
8/6/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$25.00 ➝ $21.00
7/21/2025Cantor FitzgeraldUpgradeStrong-Buy
5/7/2025GuggenheimLower TargetBuy ➝ Buy$78.00 ➝ $55.00
5/7/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$75.00 ➝ $70.00
5/7/2025BarclaysLower TargetEqual Weight ➝ Equal Weight$31.00 ➝ $25.00
4/7/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/28/2025Bank of AmericaUpgradeNeutral ➝ Buy$42.00 ➝ $42.00
3/12/2025Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
3/10/2025Jones TradingUpgradeHold ➝ Buy$34.00
3/10/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
3/10/2025WedbushReiterated RatingOutperform$57.00
3/10/2025ScotiabankUpgradeSector Perform ➝ Sector Outperform$40.00
3/3/2025ScotiabankBoost TargetSector Perform ➝ Sector Perform$24.00 ➝ $25.00
2/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
2/27/2025GuggenheimReiterated RatingBuy ➝ Buy$78.00 ➝ $78.00
2/26/2025Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$24.00 ➝ $26.00
2/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
1/29/2025Cantor FitzgeraldUpgradeNeutral ➝ Overweight
1/13/2025WedbushReiterated RatingOutperform$57.00
1/7/2025Sanford C. BernsteinUpgradeHold ➝ Strong-Buy
12/10/2024Cantor FitzgeraldUpgradeHold
12/9/2024WedbushReiterated RatingOutperform$57.00
12/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
11/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
11/6/2024Leerink PartnrsUpgradeHold ➝ Strong-Buy
11/6/2024Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$27.00 ➝ $24.00
11/6/2024Leerink PartnersUpgradeMarket Perform ➝ Outperform$27.00 ➝ $39.00
11/5/2024WedbushReiterated RatingOutperform$57.00
10/16/2024ScotiabankInitiated CoverageSector Outperform$24.00
9/19/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$27.00 ➝ $27.00
9/11/2024Stifel NicolausBoost TargetBuy ➝ Buy$66.00 ➝ $69.00
8/22/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
8/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$45.00 ➝ $48.00
8/7/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$33.00 ➝ $31.00
8/7/2024Royal Bank Of CanadaReiterated RatingSector Perform ➝ Sector Perform$27.00 ➝ $27.00
8/6/2024WedbushReiterated RatingOutperform$57.00
7/23/2024HC WainwrightInitiated CoverageBuy$80.00
5/8/2024BarclaysLower TargetEqual Weight ➝ Equal Weight$42.00 ➝ $33.00
5/7/2024WedbushReiterated RatingOutperform$57.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$57.00
3/27/2024BMO Capital MarketsReiterated RatingOutperform ➝ Outperform$57.00
2/28/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$26.00 ➝ $42.00
2/28/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$27.00 ➝ $35.00
2/27/2024WedbushReiterated RatingOutperform$48.00 ➝ $57.00
1/29/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$38.00 ➝ $40.00
1/8/2024WedbushReiterated RatingOutperform$48.00
12/15/2023Bank of AmericaDowngradeBuy ➝ Neutral$35.00
12/8/2023Jefferies Financial GroupReiterated RatingBuy ➝ Hold$75.00 ➝ $30.00
11/13/2023WedbushReiterated RatingOutperform$48.00
10/31/2023WedbushReiterated RatingOutperform$48.00
10/31/2023William BlairReiterated RatingOutperform
10/20/2023Leerink PartnrsDowngradeOutperform ➝ Market Perform
10/20/2023Cantor FitzgeraldDowngradeOverweight ➝ Neutral
10/20/2023Leerink PartnersDowngradeOutperform ➝ Market Perform$75.00 ➝ $20.00
10/17/2023Cantor FitzgeraldLower TargetOverweight ➝ Overweight$56.00 ➝ $32.00
9/13/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$56.00
8/29/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$56.00
8/9/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$46.00 ➝ $47.00
8/9/2023CitigroupLower TargetBuy ➝ Buy$60.00 ➝ $56.00
8/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$41.00 ➝ $35.00
8/8/2023WedbushReiterated RatingOutperform$79.00
5/11/2023Royal Bank Of CanadaLower Target$50.00 ➝ $42.00
5/11/2023BarclaysLower Target$45.00 ➝ $41.00
3/22/2023William BlairReiterated RatingOutperform
3/21/2023Sanford C. BernsteinInitiated CoverageMarket Perform$37.00
3/1/2023Wells Fargo & CompanyLower TargetOverweight$125.00 ➝ $105.00
1/31/2023Cantor FitzgeraldInitiated CoverageOverweight$62.00
1/23/2023Leerink PartnersLower TargetOutperform$81.00 ➝ $77.00
12/20/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$61.00 ➝ $66.00
12/13/2022CitigroupInitiated CoverageBuy$62.00
11/15/2022GuggenheimLower Target$102.00
11/8/2022Credit Suisse GroupLower TargetNeutral$65.00 ➝ $53.00
11/7/2022Leerink PartnersLower TargetOutperform$82.00 ➝ $81.00
8/10/2022BarclaysBoost TargetEqual Weight$38.00 ➝ $60.00
8/10/2022Leerink PartnersLower TargetOutperform$118.00 ➝ $113.00
8/1/2022WedbushReiterated RatingOutperform$100.00
7/18/2022BMO Capital MarketsBoost Target$41.00 ➝ $61.00
6/16/2022BMO Capital MarketsInitiated CoverageMarket Perform$41.00
4/28/2022Credit Suisse GroupInitiated CoverageNeutral$62.00
2/28/2022WedbushLower TargetOutperform$159.00 ➝ $152.00
1/10/2022WedbushBoost Target$148.00 ➝ $159.00
1/10/2022Leerink PartnersBoost TargetOutperform$116.00 ➝ $121.00
1/5/2022GuggenheimInitiated CoverageBuy$130.00
11/9/2021Leerink PartnersLower TargetOutperform$117.00 ➝ $116.00
10/19/2021Leerink PartnersInitiated CoverageOutperform$117.00
9/24/2021Stifel NicolausInitiated CoverageBuy$85.00 ➝ $120.00
9/10/2021Bank of AmericaInitiated CoverageBuy$150.00
6/29/2021WedbushBoost TargetOutperform$114.00 ➝ $149.00
5/11/2021Redburn PartnersInitiated CoverageBuy
5/3/2021Royal Bank Of CanadaInitiated CoverageSector Perform$85.00
3/8/2021BarclaysReiterated RatingOverweight ➝ Equal Weight$47.00 ➝ $90.00
3/1/2021BarclaysDowngradeOverweight ➝ Equal Weight$47.00 ➝ $90.00
2/25/2021WedbushBoost Target$42.00 ➝ $112.00
2/16/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00
1/29/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$38.00 ➝ $100.00
1/5/2021Stifel NicolausInitiated CoverageHold
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
5/8/2025
  • 25 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2025
  • 10 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 15 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/6/2025
  • 21 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 9 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 14 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 14 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 14 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Beam Therapeutics logo
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $28.91
Low: $26.35
High: $29.16

50 Day Range

MA: $24.78
Low: $20.60
High: $30.62

52 Week Range

Now: $28.91
Low: $13.52
High: $35.25

Volume

2,773,390 shs

Average Volume

2,032,009 shs

Market Capitalization

$2.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Beam Therapeutics?

The following Wall Street sell-side analysts have issued research reports on Beam Therapeutics in the last year: Bank of America Corporation, Barclays PLC, Benchmark Co., Cantor Fitzgerald, Evercore ISI, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Jones Trading, JPMorgan Chase & Co., Royal Bank Of Canada, Sanford C. Bernstein, Scotiabank, Wall Street Zen, Wedbush, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for BEAM.

What is the current price target for Beam Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Beam Therapeutics in the last year. Their average twelve-month price target is $45.58, suggesting a possible upside of 57.7%. HC Wainwright has the highest price target set, predicting BEAM will reach $80.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $21.00 for Beam Therapeutics in the next year.
View the latest price targets for BEAM.

What is the current consensus analyst rating for Beam Therapeutics?

Beam Therapeutics currently has 1 sell rating, 2 hold ratings, 11 buy ratings and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for BEAM.

What other companies compete with Beam Therapeutics?

Other companies that are similar to Beam Therapeutics include CRISPR Therapeutics, Denali Therapeutics, Editas Medicine, Intellia Therapeutics and Twist Bioscience. Learn More about companies similar to Beam Therapeutics.

How do I contact Beam Therapeutics' investor relations team?

Beam Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-327-8775 and its investor relations email address is [email protected]. The official website for Beam Therapeutics is www.beamtx.com. Learn More about contacing Beam Therapeutics investor relations.